Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Here's Why GlycoMimetics Could Become a Takeover Target

TheMotleyFool 
0 0 17.12.17
Here's Why GlycoMimetics Could Become a Takeover Target
 
Here's Why GlycoMimetics Could Become a Takeover Target

Updated results from a trial evaluating GMI-1271 in relapsed or refractory acute myeloid leukemia (AML) sent GlycoMimetics (NASDAQ: GLYC) shares soaring earlier this week, but more good news next year could send shares even higher next year.

The company plans to begin a phase 3 study of GMI-1271 by the middle of 2018, and in the second half of 2018, data is expected from a phase 3 study evaluating GlycoMimetics and Pfizer's (NYSE: PFE) sickle-cell disease drug, rivipansel.

The potential to improve AML treatment and improve the lives of sickle-cell disease patients could make this company an intriguing takeover target, so let's learn more about GlycoMimetics' story.

Continue reading


Source: Fool.com

Glycomimetics Inc. Stock

Show more
Like: 0
GLYC
Share

Comments

Not a member yet? Sign up for free!